Скачать или смотреть AI for gastric cancer treatment prediction and guidance

Hyung-Don Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, discusses using an artificial intelligence (AI) model to predict claudin 18.2 expression and immune phenotype and refine patient selection for targeted therapies like zolbetuximab in gastric cancer. The model accurately identified claudin 18.2 positivity and stratified patients by likely treatment response. In settings with limited tissue or testing resources, AI-driven prediction can help prioritize biomarker testing and guide first-line therapy, supporting more accessible and personalized use of targeted treatments. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.